


Institute Report No. 330



Acute Oral Toxicity of Physostigmine
Salicylate in Guinea Pigs

Denzil F. Frost, MS, DVM, CPT, VC and Don W. Korte, Jr., PhD, MAJ, MSC

MAMMALIAN TOXICOLOGY BRANCH
DIVISION OF TOXICOLOGY

DESTRIBUTION STATEMENT A

Approved for public releases
Distribution Unlimited

November 1988

Toxicology Series: 217

LETTERMAN ARMY INSTITUTE OF RESEARCH PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129

89 1 23 058

UNCLASSIFTED

The transfer to the second of the second of

SECURITY CLASSIFICATION OF THIS PAGE

AD	11202	783

}	REPORT DOCUMENTATION PAGE Form Approved OMB No. 0704-0188						
1a. REPORT S UNCLASS	ECURITY CLASS	SIFICATION		16 RESTRICTIVE	MARKINGS		
		N AUTHORITY		3 DISTRIBUTION	AVAILABILITY OF	REPORT	
25 DECLASSI	FICATION / DOV	VNGRADING SCHEDU	16	APPROVED	FOR PUBLIC	RELE	ASE:
20. 00003311		-			TION IS UNL		
4. PERFORMIN	NG ORGANIZAT	TON REPORT NUMBE	R(S)	5. MONITORING ORGANIZATION REPORT NUMBER(S)			
Institu	te Repor	t No.: 330					
6a. NAME OF	PERFORMING	ORGANIZATION	6b. OFFICE SYMBOL		ONITORING ORGAN		···
	an Toxic		(If applicable)		Medical Res e of Chemic		
	n of Tox (City, State, an		SGRD-ULE-T		ty, State, and ZIP Co		rense
			f Research				
	Letterman Army Institute of Research Presidio of San Francisco, CA 94129-6800			Aberdeen Proving Ground Maryland 21010-5425			
			Maryland 21010-5425				
8a. NAME OF FUNDING SPONSORING 8b. OFFICE SYMBOL				9 PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER			
ORGANIZATION US Army Medical (If applicable) Research & Development Command							
Research & Development Command 8c. AUDRESS (City, State, and ZIP Code) 10 SOURCE OF FUNDING NUMBERS							
Fort Detrick PROGRAM PROJECT TASK WORK UNIT					WORK UNIT		
		land 21701-5	5012	ELEMENT NO	NO.	NO.	ACCESSION NO.
•			62734	A875	BC	DA0H0366	
11. TITLE (Include Security Classification) (U) Acute Oral Toxicity of Physostigmine Salicylate in Guinea Pigs							
12. PERSONAL AUTHOR(S) DE Frost and DW Korte Jr							
DF Frost and DW Korte, Jr.							
13a. TYPE OF REPORT 13b. TIME COVERED 14. DATE OF REPORT (Year, Month, Day) 15 PAGE COUNT Institute FROM 7JUL87 TO24SEP87 November 1988 63							
16. SUPPLEME	NTARY NOTAT	TION					
Covical	ogy Seri	es No. 217					
17.	COSATI		18. SUBJECT TERMS (C	ontinue on revers	of pecessary and	identify b	v block number)
FIELD	GROUP	SUB-GROUP					l Toxicity,
			. Guinea Pig		•		• .
19. ABSTRACT			and identify by block nu		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
			oxicity of phy				
			guinea pigs want male and fem				
			erved were pri				
			a, irritabilit				
			al signs inclu				
lacrima			of the clinic				animals were
exhibit	ing sign	s by 24 hour	rs after dosin	g and had	either die	d or	returned to
			osing. Accord				
Hodge a	nd Stern	er, these re	esults place p	hysostigmi	ine salicyl	ate i	n the highly
toxic c	lass. κ_e	Chericas:)				
		U	-				
		LITY OF ABSTRACT			CURITY CLASSIFICA	TION	
		ED SAME AS R	PT. DTIC USERS	UNCLASS		133: 55	USE EVALUATION
	F RESPONSIBLE BEATRI	CE, COL, MC		(415) 5	include Area Code) 61–3600	ZZC. OFF	SGRD-ULZ

ABSTRACT

The acute oral toxicity of physostigmine salicylate was determined in male and female Hartley guinea pigs using the single-dose method. The median lethal dose for both male and female guinea pigs was less than 7.1 mg/kg. Clinical signs observed were primarily related to changes in behavior; such as tremors, irritability, ataxia, and inactivity. Other frequently observed clinical signs included salivation, diarrhea, and lacrimation. The duration of the clinical signs was acute. Most animals were exhibiting signs by 24 hours after dosing and had either died or returned to normal by 72 hours after dosing. According to the classification scheme of Hodge and Sterner, these results place physostigmine salicylate in the highly toxic class.



Acces	ion For	1					
DTIC Unann	NTIS CRA&I DTIC TAB Unannounced Justification						
By Distrib	By Distribution (
Availability Codes							
Dist	Avail an Speci						
A-1							

PREFACE

TYPE REPORT: Acute Oral Toxicity GLP Study Report

TESTING FACILITY:

US Army Medical Research and Development Command Letterman Army Institute of Research Presidio of San Francisco, CA 94129-6800

SPONSOR:

The second section of the second second

US Army Medical Research and Development Command US Army Medical Research Institute of Chemical Defense Aberdeen Proving Ground, MD 21010-5425 Project Officer: LTC J. von Bredow, PhD, MSC

PROJECT/WORK UNIT/APC: 3M162734A875/308/TLE0

GLP STUDY NUMBER: 87008

STUDY DIRECTOR: Don W. Korte, Jr., PhD, MAJ, MS

PRINCIPAL INVESTIGATOR: Denzil F. Frost, MS, DVM, CPT, VC

Diplomate, American College of Veterinary Preventive Medicine

PATHOLOGIST: Charles B. Clifford, DVM, PhD, MAJ, VC

Diplomate, American College of Veterinary

Pathologists

DATA MANAGER: Yvonne C. LeTellier, BS

REPORT AND DATA MANAGEMENT: A copy of the final report,

study protocols, retired SOPs, raw data, analytical, stability, and purity data of the test compound, and an aliquot of the test compound will be retained in

the LAIR Archives.

TEST SUBSTANCE: Physostigmine Salicylate

INCLUSIVE STUDY DATES: 7 July - 24 September 1987

OBJECTIVE: The objective of this study was to determine the acute oral toxicity of physostigmine salicylate in male and female Hartley guinea pigs.

ACKNOWLEDGMENTS

A POST OF THE PROPERTY OF THE PARTY OF THE P

SPC Dean Magnuson, BS, and SPC Joel B. Seewald, BS, provided research assistance; SGT John R. G. Ryabik, BS, provided chemical preparation and analysis; SGT Tammie R. Heineman, SGT Chuck Fteedman, and Richard A. Spieler provided animal care and facility management; and Marie Rogers and Mara Joshua provided secretarial assistance.

SIGNATURES OF PRINCIPAL SCIENTISTS AND MANAGERS INVOLVED IN THE STUDY

We, the undersigned, declare that study number 87008 was performed under our supervision, according to the procedures described herein, and that this report is an accurate record of the results obtained.

DON W. KORTE, JR PhD/DATE

MAJ, MS

Study Director

CONRAD R. WHEELER, PhD/DATE

DAC

Analytical Chemist

DENZIL F. FROST, MS, DVM/DATE

CPT, VC

Principal Investigator

YVONNE C. LETELLIER, BS/DATE

DAC

Data Manager

Challes 3 Cliffy / Dec 88

MAJ, VC

Pathologist



DEPARTMENT OF THE ARMY

LETTERMAN ARMY INSTITUTE OF RESEARCH PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129-6800

ATTENTION OF

SGRD-ULZ-OA

30 November 1988

MEMORANDUM FOR RECORD

SUBJECT: GLP Compliance for GLP Study 87008

1. This is to certify that in relation to LAIR GLP Study - Protocol Review
- Dosing and Observations (Phase I)
04 August 1987 - Final Sacrifice (Phase I)
08 September 1987 - Dosing (Phase II)
08 September 1987 - Observations (Phase II)
22 September 1987 - Final Observations (Phase II)
22 September 1987 - Final Sacrifications (Phase II)
23 September 1987 - Final Sacrifications (Phase II) 87008, the following inspections were made:

2. The institute report entitled "Acute Oral Toxicity of Physostigmine Salicylate in Guinea Pigs, "Toxicology Series 217, was audited on 14 November 1988.

Carolyn M. LEWIS

Chief, Quality Assurance

TABLE OF CONTENTS

the bearing and the second

	Page
Abstract	i
Preface	.iii
Acknowledgments	iv
Signatures of Principal Scientists	v
Report of Quality Assurance Unit	vi
Table of Contents	.vii
INTRODUCTION	1
Objective of Study	2
MATERIALS	2
Test Substance Vehicle Animal Data Husbandry	2
METHODS	3
Group Assignment/Acclimation. Dosage Levels	3
RESULTS	6
Mortality Lethal Dose Calculations Clinical Observations Pathology Findings	6
DISCUSSION	13

TABLE OF CONTENTS (cont.)

<u>Pa</u>	ge
CONCLUSION1	16
REFERENCES1	
APPENDICES	8
Appendix A. Chemical Data	22 23 26 27
OFFICIAL DISTRIBUTION LIST6	54

Acute Oral Toxicity of Physostigmine Salicylate in Guinea Pigs -- Frost and Korte

INTRODUCTION

Soman, the primary nerve agent utilized by threat forces, is refractory to the standard antidotal therapy, atropine and pralidoxime (2-PAM), fielded by the US Army. Consequently, the highest priority has been placed on fielding a more effective treatment regimen. A regimen incorporating pyridostigmine as a prophylactic agent, combined with standard atropine/2-PAM therapy, has proven extremely effective in reducing mortality of Rhesus monkeys to multilethal concentrations of soman (1). However, these animals require a prolonged period of recovery during which they are completely incapacitated. This has been attributed to the quaternary nature of pyridostigmine, which does not cross the blood-brain barrier and thus only protects the peripheral nervous system. Consequently, a tertiary carbamate, physostigmine, has been proposed for the prophylactic regimen since it would protect the central nervous system in addition to the peripheral nervous system. Experimental studies support this hypothesis as animals pretreated with physostigmine before exposure to soman recover at a faster rate than animals pretreated with pyridostigmine (2,3). An enhanced rate of recovery of soldiers from a multilethal exposure to soman would produce a decided advantage in maintaining a fully functional military unit during a future conflict.

The only approved formulation of physostigmine is for intravenous administration, which is not a feasible option for the proposed prophylactic therapy. Either the oral or dermal route of administration for prophylactic therapy would be feasible. However, even though physostigmine has been available for more than a century (4), little directed research on its toxicology following oral or dermal administration has been conducted. Consequently, the Division of Toxicology, Letterman Army Institute of Research, was tasked by the US Army Medical Research Institute of Chemical Defense to provide an acute and subchronic toxicity profile of physostigmine salicylate following oral and subcutaneous administration.

Objective of Study

The objective of this study was to determine the acute oral toxicity of physostigmine salicylate in male and female Hartley guinea pigs.

MATERIALS

Test Substance

Chemical Name: Physostigmine salicylate

Chemical Abstracts Service Registry No.: 57-64-7

Chemical Structure:

$$\begin{array}{c|c} CH_3 & CH_3 \\ \hline \\ NH_2 \\ CH_3 & CH_3 \end{array} - \infty C \longrightarrow \begin{array}{c} CH_3 \\ NH_2 \\ + \end{array}$$

Molecular Formula: C15H21N3O2 • C7H6O3

Source: Mr. William Ellis

Division of Experimental Therapeutics Walter Reed Army Institute of Research Requested by LTC J. von Bredow, USAMRICD

Other test substance information is presented in Appendix A.

Vehicle

The vehicle for physostigmine salicylate was sterile water (Abbott Labs, North Chicago, IL 60064). The expiration date was 1 February 1989, and the lot number was 01-075-FW.

Animal Data

Forty-seven male and 87 female Hartley guinea pigs (Charles River Laboratories, Inc., Kingston, NY) were used for this study. They were identified individually with ear tags. Two additional males and three females from the shipment were

randomly selected for quality control necropsy. The animal weights on receipt (8 Jul 87, 28 Aug 87) ranged from 188 g to 265 g. Additional animal data appear in Appendix B.

Husbandry

Guinea pigs were caged individually in stainless steel wire-mesh cages with automatic flushing dumptanks. No bedding was used in any of the cages. The diet, fed ad libitum, consisted of Certified Purina Guinea Pig Chow® Diet 5026 (Ralston Purina Company, St. Louis, MO); water was provided by continuous drip from a central line. The animal room temperature was maintained in a range from 17.7°C to 25.6°C with a relative humidity range of 38% to 67%. The photoperiod was 12 hours of light per day.

METHODS

Group Assignment/Acclimation

Study animals were randomized into 5 dose groups of 8 males each, 4 dose groups of 8 females each, 3 dose groups of 16 females each, and vehicle control groups of 5 males and 5 females each. Allocation was accomplished using a computer-based, stratified, weight-biased method. The Beckman TOXSYS® Animal Allocation Program was used in conjunction with a Beckman TOXSYS® Data Collection Terminal. The animals were acclimated for 12-19 days before the day of dosing. During this period they were observed daily for signs of illness.

Dosage Levels

The ALD determination indicated that the median lethal dose (MLD) was between 5 and 7.5 mg/kg. Based on these data, test dosages were selected (Table 1).

Compound Preparation

Specific concentrations for dosing were prepared in sterile water for injection (Abbott Laboratories, North Chicago, IL 60064, Lot No. 01-075-FW).

TABLE 1: Physostigmine Salicylate Dosages

Group	Dosage Level (mg/kg)
Phase I (males	and females)
1	5.62
2	6.31
3	6.65
4	7.08
5	7.50
6 (vehicle control)	-
Phase II (fe	emales only)
1	5.62
3	6.65
5	7.50
7	4.47
8	8.91

Chemical Analysis of Dosing Solution

The concentration of physostigmine salicylate in the dosing solutions was defermined by UV spectrophotometry (Appendix A). Actual concentrations of physostigmine salicylate in the dosing solutions ranged from 96.8% to 99.6% of the target concentration.

Test Procedures

This study was conducted in accordance with LAIR SOP OP-STX-36 (5).

The volume of dosing solution each animal received was based upon the desired dose level, the compound's concentration in suspension, and the animal's weight. Volumes ranged from 2.1 ml to 3.5 ml in the males and from 2.4 ml to 3.8 ml in females. The vehicle control group was given 2.7 ml to 3.3 ml sterile water. The volumes given were based on 10 ml/kg. Dosing was performed using the oral gavage method without animal sedation or anesthesia. Sterile disposable syringes (Becton, Dickerson & Co, Rutherford, NJ) fitted with 5-French feeding tubes (Seamless Hospital Products Co., Division of Dart Industries, Inc., P.O. Box 828, Wallingford, CN) were used for dosing. Phase I animals were dosed between 0745 and 1336 hours on 21 Jul 87 and 0737 and 0903 on 23 Jul 87; Phase II animals were dosed between 0943 and 1020 hours on 8 Sep 87, 0921 and 0939 on 10 Sep 87, and 0900 and 0919 on 15 Sep 87.

Observations

all the second of the second of the second of

Observations for mortality and signs of acute toxicity were performed daily according to the following procedure:

(a) animals were observed undisturbed in their cages; (b) animals were removed from their cages and given a physical examination; and (c) animals were observed after being returned to their cages. On the day of the dosing, the animals were checked intermittently throughout the day. Recorded observations were performed 1, 2, and 4 hours after dosing, and daily for the remainder of the 2 week test period. A second "walk-through" observation was performed daily and only significant observations recorded. Body weights were recorded once weekly during the course of the study.

Necropsy

Animals that died during the observation period were submitted for a complete gross necropsy. Those which survived the 14-day study period were submitted for necropsy immediately after sacrifice by barbiturate overdose.

Statistical Analysis

Statistical analyses were performed on the study results. The LD10, LD50, and LD90 were derived by the maximum likelihood method of probit analysis, as described by Finney (6). The program, PROBIT, developed for the Data General Computer, Model MV8000, was used to plot the probit curve and lethal dose values.

Duration of Study

Appendix C is a complete listing of historical events.

Changes/Deviations

The dosing phase of this study was accomplished according to the protocol and applicable amendments with the following exceptions: The dosage levels for Phase I and II were differentiated between males and females to allow a more accurate MLD determination for each sex, and pediatric feeding tubes were used in place of metal dosing needles to minimize potential trauma to the oral and esophageal mucosa. It is believed that none of these changes had any adverse effect on the results of this study.

Storage of Raw Data and Final Report

A copy of the final report, study protocol, raw data, retired SOPs and an aliquot of the test compound will be retained in the Letterman Army Institute of Research Archives.

RESULTS

Mortality

Sixty-three animals died as a result of the dosing. Fifty-one (81%) deaths occurred within 12 hours of dosing. An additional 11 (17%) deaths occurred by 48 hours after dosing. Table 2 lists the compound-related deaths by group and the percent mortality. Appendix D is a tabular presentation of cumulative mortality.

Lethal Dose Calculations

Lethal dose values were calculated by probit analysis, and the equation for the probit regression line was: $Y = -0.47 + 6.44 \log X$ (males) and $Y = 0.66 + 5.61 \log X$ (females), where X is the dose and Y the corresponding probit value. Lethal doses calculated from the equation for the probit regression line are presented in Table 3. Figures 1 and 2 graphically present the actual data points and the regression line.

TABLE 2: Compound-Related Deaths by Group

Group	Dose Level (mg/kg)	Compound Related Death/ Number in Group	Percent Mortality
-		MALES	
1	5.62	3/ 8	38
2	6.31	1/ 8	13
3	6.65	4/8	50
4	7.08	4/8	50
5	7.50	5/ 8	63
6	Control	0/5	0
		FEMALES	
7	4.47	2/8	25
1	5.62	8/16	50
2	6.31	5/ 8	63
3	6.65	9/16	56
4	7.08	5/ 8	63
5	7.50	9/15	60
8	8.91	8/8	100
6	Control	0/ 5	0

Clinical Observations

the surgestion than the best of the supplementary about the control of the

Fifty-one out of 129 dosed animals died within 12 hours of dosing. Clinical signs, in many cases, were observed before death. Many of the surviving 79 dosed animals exhibited clinical signs within the first 24 hours after dosing. The clinical observations included gastrointestinal, behavioral, reflexive, skin/fur, urogenital, and ocular signs.

TABLE 3: Calculated Lethal Doses (LD) of Physostigmine Salicylate in Sprague-Dawley Rats

Level	Calculated Dose* (mg/kg)	
	MALES	
LD10	4.48 ± 1.35	
LD50	7.08 ± 0.62	
LD90	22.0 ± 2.57	
	FEMALES	
17010	3.51 ± 0.78	
LD50	5.94 ± 0.40	
LD90	10.05 ± 1.66	

^{*} Calculated dose ± standard error

The most frequently observed category of signs was gastrointestinal disturbances (72 of 129 animals). Gastrointestinal signs exhibited by the animals included salivation, diarrhea, tarry feces, stain or material found on animal, and emaciation. Gastrointestinal signs were present in all dose groups but did not exhibit a dose-response relationship. Other classes of clinical signs observed and their frequencies included: behavioral (15/129), reflexive (1/129), skin/fur (7/129), ocular (1/129), and urogenital (1/129). Of interest was one prolapsed uterus 2 days after desing (animal 87E00201).

Most clinical signs had cleared by 72 hours after dosing, with the exception of diarrhea, inactivity, staining, pallor, tarry feces, rough coat, and emaciation. Twenty-five animals died within the first 48 hours without clinical signs being detected. Additional deaths with clinical signs observed occurred up to 4 days after dosing. Tables 4 and 5 contain a summary of clinical observations. Appendix E contains individual animal histories.




Figure 1: Physostigmine Dose Response Curve in Male Guinea Pigs




Figure 2: Physostigmine Dose Response Curve in Female Guinea Pigs

TABLE 4

Incidence Summary for Clinical Observations in Male Guinea Pigs Administered Physostigmine Salicylate

7.50 Vehicle	n	1 - 1
7.50	∞	e e e
7.08	Σ .	1 10 1
6.65	Σ	1 m 1
6.31	χ	H 25 H
5.62	æ	1501
Dose (mg/kg)	(n=)	
	Clinical Signs	Behavior ^a Gastrointestinal ^b Skin/fur ^c

^bIncludes increased salivation, diarrhea, tarry feces, stains or material found on animal, alncludes inactive and tremors. and emaciation.

cincludes rough coat.

TABLE 5

Incidence Summary for Clinical Observations in Female Guinea Pigs Administered Physostigmine Salicylate

	Dose (mg/kg)	4.47	5.62	6.31	6.65	7.08	7.50	8.31	Vehicle
Clinical Signs	(n=)	89	16	ထ	16	ω	15	ထ	Ŋ
General ^a Behavior ^b Refiexes ^c Ocular ^d Gastrointestinal ^e Skin/fur ^f Urogenital ^g		1441701	IIII O MM m	ाला 1 छल्ट	1011001	11116011	191761;	1~11011	1111011

aIncludes hunched posture.

bincludes inactive, ataxia, paralysis, and tremers.

cIncludes loss of equilibrium.

dincludes lacrimation.

*Includes increased salivation, diarrhea, tarry feces, stains or material found on animal, and emaciation.

fincludes pallor and rough coat.

gincludes prolapsed uterus.

Weight gains of survivors were not significantly affected by dosing. Tables 6(a) and 6(b) present the mean body weights by groups. Appendix F contains individual weight tables.

Pathology Findings

There were no lesions observed at necropsy in those animals euthanized after the 14-day observation period. The majority of animals that died during the study presented with a serous oral discharge, perianal staining, and intussusception, observations consistent with the actions of a parasympathomimetic agent. Appendix G contains the complete pathology report.

DISCUSSION

The acute oral administration of physostigmine salicylate to Hartley guinea pigs produced pronounced toxicological effects. The calculated median lethal dose (MLD) for physostigmine salicylate in this study was 7.08 mg/kg in male and 5.94 mg/kg in female guinea pigs. These MLD values place physostigmine in the highly toxic classification (1-50 mg/kg) of Hodge and Sterner (7).

The toxicity observed following physostigmine administration was consistent with massive cholinergic stimulation following cholinesterase inhibition (8). Toxic signs attributable to excessive muscarinic stimulation included lacrimation, salivation, and diarrhea. The nicotinic effects observed included tremors, irritability, inactivity, and ataxia as the animals became fatigued. These effects were observed primarily in surviving animals since many animals that received the higher doses died without exhibiting the spectrum of toxic signs observed in animals receiving the lower doses.

The two cases of ileocolic intussusceptions observed in animals 87E00239 and 87E00257 at necropsy is probably related to the acetylcholine release that occurs following physostigmine salicylate administration (8). The prolonged toxicity and late death observed in one female (87E00228) administered 6.31 mg/kg physostigmine salicylate was not expected since the half-life of physostigmine is short in all species tested (9). The mechanism for this delayed toxicity cannot be elucidated from this study. If the delayed toxicity is due to a direct pharmacological effect, it will become readily apparent in subchronic toxicity studies scheduled to be conducted in several species.

A SECTION OF THE SECT

TABLE 6(a): Mean Body Weights of Male Guinea Pigs Administered Physostigmine Salicylate

Dose Groups (mg/kg)	At Receipt	At Dosing	Day 7	Termination Day 14*
5.62	235.1 [†]	303.0	349.6	360.6
	±4.6(8)	±7.7(8)	±23.5(5)	±19.9(5)
6.31	230.1	300.1	335.7	347.0
	±6.2(8)	±5.2(8)	±20.3(7)	±25.1(7)
6.65	228.1	304.5	375.5	391.0
	±7.4(8)	±14.7(8)	±18.1(4)	±20.2(4)
7.08	228.9	304.0	349.3	363.5
	±5.7(8)	±7.1(8)	±6.5(4)	±9.7(4)
7.50	228.9	301.4	359.3	366.3
	±6.3(8)	±8.6(8)	±21.2(3)	±27.7(3)
Vehicle	229.4	305.0	371.6	380.2
Control	±3.2(5)	±8.9(5)	±10.8(5)	±16.1(5)

^{*}Weight after overnight fast.

[†]Values are mean ± standard error (number of animals) in grams.

TABLE 6(b): Mean Body Weights of Female Guinea Pigs Administered Physostigmine Salicylate

Dose Groups (mg/kg)	At Receipt	At Dosing	Day 7	Termination Day 14*
4.47	235.0†	293.8	317.7	313.3
	±8.8(8)	±14.2(8)	±20.4(6)	±26.9(6)
5.62	233.2	287.5	324.8	327.1
	±4.8(16)	±8.4(16)	±15.4(8)	±14.9(8)
6.31	230.1	273.4	328.0	334.3
	±5.6(8)	±8.9(8)	±9.8(3)	±10.5(3)
6.65	235.1	289.7	340.9	349.1
	±6.6(16)	±4.4(16)	±10.2(7)	±10.6(6)
7.08	236.3	287.6	340.7	333.7
	±3.8(8)	±3.9(8)	±5.7(3)	±10.7(3)
7.50	242.9	278.1	329.5	335.2
	±4.3(15)	±6.4(15)	±16.4(6)	±16.0(6)
8.91	252.8 ±8.8(8)	342.4 ±9.3(8)	-	-
Vehicle	216.8	276.8	329.4	329.2
Control	±7.2(5)	±6.0(5)	±3.6(5)	±3.7(5)

^{*}Weight after overnight fast.

[†]Values are mean ± standard error (number of animals) in grams.

CONCLUSION

Physostigmine salicylate is a highly toxic compound that produces clinical signs associated with cholinergic stimulation. Calculated MLD values after oral administration were 7.08 mg/kg in male and 5.94 mg/kg in female Hartley guinea pigs.

REFERENCES

 Kluwe WM, Chinn JC, Feder P, Olson C, Joiner R. Efficacy of pyridostigmine pretreatment against acute soman intoxication in a primate model (Paper No. IX-1). In: Proceedings of the sixth medical chemical defense bioscience review. Columbia, MD (4-6 Aug) 1987:227-234.

and Annual Control of the Control of

- Leadbeter L, Inns RH, Rylands JM. Treatment of poisoning by soman. Fundam Appl Toxicol 1985; 5:S225-S231.
- 3. Harris LW, McDonough JH, Sticher DL, Lennox WJ. Protection against both lethal and behavioral effects of soman. Drug Chem Toxicol 1984; 7:605-624.
- 4. Karczmar AG. History of the research with anticholinesterase agents. In: International Encyclopedia of Pharmacology and Therapeutics, 1970 (Section 13) 1:1-8.
- 5. Acute oral toxicity study (ALD and LD50). LAIR
 Standard Operating Procedure OP-STX-36, Letterman Army
 Institute of Research, Presidio of San Francisco, CA, 15
 June 1984.
- 6. Finney DJ. Probit analysis. 3rd ed. Cambridge: Cambridge University Press, 1981:20-80.
- 7. Hodge HC, Sterner JH. Tabulation of toxicity classes. American Industrial Hygiene Association Quarterly 1943; 10:93-96.
- 8. Taylor P. Anticholinesterase agents. In: Gilman AG, Goodman LE, Rall TW, Murad F, eds. The pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Co, Inc, 1985; 110-129.
- 9. Somani SM, Khaligue A. Pharmacokinetic and pharmacodynamic of physosligmine in the rat after intravenous administration. Drug Metab Dispos 1987;15:627-633.

STATE OF THE PARTY OF THE PARTY

APPENDICES

	Pa	ige
APPENDIX A.	Chemical Data	19
APPENDIX B.	Animal Data	22
APPENDIX C.	Historical Listing of Study Events	23
APPENDIX D.	Cumulative Mortality Data	26
APPENDIX E.	Individual Animal Histories	27
APPENDIX F.	Individual Bedy Weights	44
APPENDIX G.	Pathology Report	57

APPENDIX A: Chemical Data

Chemical Name: Physostigmine salicylate

Other Names: Eserine salicylate; Physostigmine, 2-hydroxybenzoate; 1, 2, 3, 3a, 8, 8a-Hexahydro-1, 3a, 8-trimethylpyrrolo[2,3-b]indol-5-ol methylcarbamate (ester), (3aS-cis)-, mono (2-hydroxybenzoate) (salt)

Lot Number: BL25591

Chemical Abstracts Service Registry Number: 57-64-7

LAIR Code: TW73

The same of the same was the death and the same will be said the same of the s

WRAIR Code: WR 6570AM

Chemical Structure:

Molecular Formula: C15H21N3O2 • C7H6O3

Molecular Weight: 413.47

Analytical Data:

The test compound was analyzed by the sponsors and the identity confirmed by UV and IR spectroscopy, high pressure liquid chromatography, mass spectrometry and elemental analysis. Based on HPLC analysis of this test compound in comparison with the USP physostigmine salicylate reference standard, lot BL25591 contains 66.7% (100.1% of theory) physostigmine base and 33.7% (100.8% of theory) salicylic acid or 100.4% physostigmine salicylate. I

HPLC analysis of physostigmine salicylate in this lab was performed using a Hewlett-Packard 1090 HPLC system equipped with a diode array detector. The compound was chromatographed under the following conditions: silica

Marie Carlot

APPENDIX A (cont.): Chemical Data

column (4.6 x 100 mm, Brownlee Labs, Inc.); mobile phase, 15% acetonitrile/buffer (0.01M Na₂HPO₄ with 0.0025M tetramethyl-ammonium chloride); flow rate, 1.5 ml/min; wavelength monitored, 210 nm. The compound eluted as two peaks with retention times of 0.9 min (salicylic acid), and 3.9 min (physostigmine).²

IR (KBr): 3320(broad), 2964, 2325, 1744, 1629, 1594, 1485, 1460, 1383, 1326, 1245, 1203, 1184, 1151, 1140, 1087, 1006, 993, 944, 860, 807, 754, 704, 667, 382 cm $^{-1}$. The IR spectrum was identical to that provided by the sponsors.

Source: Bill Ellis

Division of Experimental Therapeutics Walter Reed Army Institute of Research

Washington, DC

Requested by LTC Jurgen von Bredow, PhD, MSC

¹Masamori E, Benitez A, and Lim P. Assay of physostigmine salicylate, WR-6570AM, BL25591. Menlo Park, CA: SRI International, 4 November 1986; Report no. 553.

²Wheeler CR. Toxicity testing of antidotes of chemical warfare agents. Laboratory notebook #85-12-024.1, pp 2-11. Letterman Army Institute of Research, Presidio of San Francisco, CA.

³Wheeler CR. Toxicity testing of antidotes of chemical warfare agents. Laboratory notebook #85-12-024.3, pp 10-11. Letterman Army Institute of Research, Presidio of San Francisco, CA.

APPENDIX A (cont.): Chemical Data

Analysis of Physostigmine Salicylate Dosing Solutions

The concentration of physostigmine salicylate in dosing solutions was determined by UV absorbance at 298 nm. Each solution was diluted and the absorbance measured by a Hitachi 110A Spectrophotometer. Using an extinction coefficient of 6222 L/moles·cm the concentration of physostigmine salicylate was calculated. The concentrations of dosing solutions for GLP study number 87008 are presented below:

Date Sample	Date Sample	Concentration	(mg/ml)	% Target
Prepared	Analyzed	Target	Actual	Conc.
20 July 87	20 July 87*	0.562	0.546	97.1
20 July 87	20 July 87	0.631	0.627	99.4
20 July 87	22 July 87+	0.631		96.8
22 July 87	22 July 87	0.665	0.654	98.3
22 July 87	22 July 87	0.708		98.0
22 July 87	22 July 87	0.750	0.737	98.3
8 Sep 87	8 Sep 87 [†]	0.750		99.6
8 Sep 87	8 Sep 87	0.665	0.654	98.3
8 Sep 87	8 Sep 87	0.562		98.6
15 Sep 87	15 Sep 87§	0.891	0.863	96.9

^{*}Wheeler CR. Toxicity testing of antidotes for chemical warfare agents. Laboratory Notebook #85-12-024, p 67. Letterman Army Institute of Research, Presidio of San Francisco, CA.

and the same of th

^{*}Wheeler CR. Toxicity testing of antidotes for chemical warfare agents. Laboratory Notebook #85-12-024.3, p 20. Letterman Army Institute of Research, Presidio of San Francisco, CA.

[†]Wheeler CR. Toxicity testing of antidotes for chemical warfare agents. Laboratory Notebook #85-12-024.1, p 66. Letterman Army Institute of Research, Presidio of San Francisco, CA.

[§] Ibid. p 67.

The British Red Laboratory and the Control of the

APPENDIX B: Animal Data

Species: Cavia porcellus

Strain: Hartley

Source: Charles River Laboratories, Inc.

Kingston, NY

Sex: Male and female

Date of birth: Male: 19 June 1987

Female: 19 June and 5 August 1987

Method of randomization: Weight bias, stratified animal

allocation (Beckman TOXSYS® Animal Allocation Program, SOP OP-ISG-24)

8 male and 16 female animals in Animals in each group:

Groups 1, 3, and 5(except 15 females in Group 5); 8 male and 8 female animals in Groups 2 and 4; 8 females in Groups 7 and 8; 5 male and 5 female animals for the

vehicle control (Group 6).

Condition of animals at start of study: Normal

Body weight range at desing: 210 - 384 g

Identification procedures: Ear Tag.

Pretest conditioning: Quarantine/acclimation

Phase I: 8 - 20 July 1987
Phase II: 28 August - 7 September 1987

Justification: The guinea pig has proven to be a

sensitive and reliable animal model for

lethal dose determinations.

APPENDIX C: Historical Listing of Study Events

Date	<u>Event</u>					
7 Jul 87	Received 57 male and 56 female Hartley guinea pigs. Animals were sexed and individually caged (Phase I).					
8 Jul 87	Four animals (2 male and 2 female) were submitted for necropsy quality control. All animals were checked for physical condition, weighed, and given ear tags.					
8-20 Jul 87	Animals were observed daily.					
13 Jul 87	Animals were weighed and randomized into dose groups.					
20 Jul 87	Animals (Groups 1 and 2) were weighed and removed from quarantine. Food was removed by 1800					
21 Jul 87	Animals (Groups 1 and 2) were weighed and dosed at approximately 0900. Observations were conducted at 1, 2, and 4 hours after dosing. Food was re-introduced 2-4 hours after dosing.					
22 Jul 87	Animals (Groups 3 - 6) were weighed and removed from quarantine. Food was removed by 1800					
23 Jul 87	Animals (Groups 3 - 6) were weighed and dosed at approximately 0900. Observations were conducted at 1, 2, and 4 hours after dosing. Food was re-introduced 2-4 hours after dosing.					
22 Jul - 4 Aug 87	Animals were observed for clinical signs in AM and PM (Groups 1 and 2).					
24 Jul - 6 Aug 87	Animals were observed for clinical signs in AM and PM (Groups $3-6$).					
28 Jul 87	Animals were weighed (Groups 1 and 2).					
30 Jul 87	Animals were weighed (Groups 3 - 6).					
3 Aug 87	Food was removed by 1800 (Groups 1 and 2).					

APPENDIX C (cont.): Historical Listing of Study Events

Date	Event
4 Aug 87	Animals (Groups 1 and 2) were weighed and observed for clinical signs. Animals were delivered to Necropsy Suite.
5 Aug 87	Food was removed by 1800 (Groups 3 - 6).
6 Aug 87	Animals (Groups 3 - 6) were weighed and observed for clinical signs. Animals were delivered to Necropsy Suite.
27 Aug 87	Phase II animals (females) arrived and were sexed, observed for illness, and individually caged. Forty-one females were assigned to the study.
28 Aug 87	Animals were tagged and weighed, and one female QC animal was submitted to necropsy.
28 Aug - 7 Sep 87	Animals were observed daily while under quarantine.
31 Aug 87	Animals were weighed and randomized into dose groups.
4 Sep 87	All animals were weighed and removed from quarantine.
7 Sep 87	Food was removed by 1800 (Groups 1, 3, and 5).
8 Sep 87	Animals (Groups 1, 3, and 5) were weighed and dosed at approximately 0900. Observations were conducted 1, 2, and 4 hours after dosing.
9-21 Sep 87	Animals (Groups 1, 3, and 5) were observed for clinical signs in AM and PM
9 Sep 87	Food was removed by 1800 (Group 7).
10 Sep 87	Animals (Group 7) were weighed and dosed at approximately 0900. Observations were conducted 1, 2, and 4 hours after dosing.
11-23 Sep 87	Animals (Group 7) were observed for clinical signs in AM and PM.

APPENDIX C (cont.): Historical Listing of Study Events

<u>Date</u>	<u>Event</u>
14 Sep 87	Food (Group 8) was removed by 1800.
15 Sep 87	Animals (Groups 1, 3, and 5) were weighed.
15 Sep 87	Animals (Group 8) were weighed and dosed at approximately 0900. Observations were conducted 1, 2, and 4 hours after dosing. All died and were submitted to the Necropsy Suite on 15 Sep 87, except for # 240 and 248 which were sent to necropsy on 16 Sep 87.
17 Sep 87	Animals (Group 7) were weighed.
21 Sep 87	Food (Groups 1, 3, and 5) was removed by 1800.
22 Sep 87	Animals (Groups 1, 3, and 5) were weighed and observed for clinical signs at approximately 0730. Animals were delivered to Necropsy Suite.
23 Sep 87	Food (Group 7) was removed by 1800.
24 Sep 87	Animals (Group 7) were weighed and observed for clinical signs at approximately 0730. Animals were delivered to Necropsy Suite.

APPENDIX D: Cumulative Mortality Data (Death/Group)
(8 Animals Per Group)

Time Res		Doos	na									
Time After Dosing												
Dose mg/kg	1	lour: 2	s 4	12	1	Days 2	3	4	5	6	7	8-14
Males												
5.62	0	0	1	3	3	3	3	3	3	3	3	3
6.31	0	0	0	0	0	1	1	1	1	1	1	1
6.65	0	0	ī	3	4	4	4	4	4	4	4	4
7.08	0	0	2	3	4	4	4	4	4	4	4	4
7.50	0	0	0	3	3	5	5	5	5	5	5	5
0*	0	0	0		0	0	0	0	0	0	0	0
					F	emal	. e s					
4.47	0	0	0	1	1	2	2	2	2	2	2	2
5.62†	1	1	3	7	7	8	8	8	8	8	8	8
6.31	1	1	2	2	4	4	4	5	5	5	5	5
6.65†	2	2	б	9	9	9	9	9	9	9	9	9
7.08	0	0	0	5	5	5	5	5	5	5	5	5
7.50\$	0	0	4	7	8	9	9	9	9	9	9	9
8.91	0	0	4	8	3	8	8	8	8	8	8	8
0 *	0	0	0		0	0	0	0	0	0	0	0
TOTAL	4	4	23	51	56	62	62	63	63	63	63	63

^{* 5} animals per group † 16 animals per group \$ 15 animals per group

APPENDIX E: INDIVIDUAL ANIMAL HISTORIES

MALE: 5.62 mg/kg Physostigmine salicylate

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00116	Stain, Brown, Perianal Increased Salivation	July 21 July 21	Slight Slight
87E00124	Increased Salivation Death	July 21 July 23	Slight 7.3 h
87E00128	Normal	N/A	N/A
87E00133	Stain, Yellow, Perianal	August 1	Slight
87E00140	Death	July 21	4 h
87E00147	Stain, Brown, Perianal	July 21-31 August 2,3	Moderate
87E00151	Death	July 22	30 h
87E00152	Diarrhea	August 2,3	Present

Frost and Korte- 28

APPENDIX E (cont.): INDIVIDUAL ANIMAL HISTORIES

MALE: 6.31 mg/kg Phyrostigmine salicylate

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00115	Increased Salivation Death	July 21 July 23	Present 43.2 h
87E00132	Increased Salivation	July 21	Present
87E00137	Normal	N/A	N/A
87E00146	Tarry Feces	July 27,28	Present
871:00156	Stain, Brown, Perianal Inactive Rough Coat Diarrhea Emaciated	July 21-30 July 25-30 July 26-Aug 3 July 29-Aug 3 Aug 1-3	
87E00163	Normal	N/A	N/A
87E00167	Normal	N/A	N/A
87E00170	Stain, Brown, Perianal	July 21-25	Slight

MALE: 6.65 mg/kg Physostigmine salicylate

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00118	Normal	N/A	N/A
87E00120	Death	July 23	6.6 h
87E00136	Normal	N/A	N/A
87E00143	Normal	N/A	N/A
87E00144	Death	July 24	24 h
87E00149	Stain, Brown, Perianal Death	July 23 July 23	Moderate 4.0 h
87E00168	Increased Salivation	July 23	Present
87E00171	Increased Salivation Death	July 23 July 23	Present 5.5 h

Frost and Korte--30

MALE: 7.08 mg/kg Physostigmine salicylate

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00122	Death	July 23	3.6 h
87E00123	Death	July 23	3.6 h
87E00127	Stain, Brown, Porianal Stain, Yellow, Perianal	July 24 July 25-30	Slight Sl ight
87E00131	Death	July 23	6.6 h
37200138	Diarrhea	August 2,3	Present
87E00142	Normal	N/A	N/A
87E00159	Death	July 24	24 h
87E00165	Stain, Brown, Perianal Stain, Yellow, Perianal	July 23 July 24-Aug 5	Slight Slight

MALE: 7.50 mg/kg Physostigmine salicylate

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00117	Normal	N/A	N/A
87E00119	Normal	N/A	N/A
87E00141	Increased Salivation	July 23	Present
	Death	July 23	6.2 h
87E00150	Increased Salivation	July 23	Present
	Inactive	July 23	Slight
	Death	July 23	4.7 h
87E00153	Tremors	July 24	Moderate
	Inactive	July 24	Moderate
	Rough Coat	July 24	Moderate
	Death	July 25	48 h
87E00154	Inactive	July 23	Slight
	Diarrhea	August 5	Present
87E00157	Death	July 25	48 h
87E00166	Stain, Yellow, Perianal	July 23	Slight
	Death	July 23	5.6 h

Fiost and Korte--32

APPENDIX E (cont.): INDIVIDUAL ANIMAL HISTORIES

MALE: Vehicle Control

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00121	Normal	N/A	N/A
87E00125	Norma!	N/A	N/A
87E00135	Stain, Brown, Perianal Diarrhea	July 23 Aug 4,5	Slight Present
8 7E00155	Normal	N/A	N/A
37E00138	Normal	N/A	N/A

Marine All States and States and the second second second

FEMALE: 5.62 mg/kg Physostigmine :alicylate

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00172	Stain, Brown, Perlanal Increased Salivation Diarrhea	July 21-31 July 21 July 27-31	Slight Moderate Present
87E00177	Normal	N/A	N/A
87E00186	Death	July 21	0.1 h
87E00201	Normal	N/A	N/A
87E00211	Stain, Brown, Perianal Increased Salivation Death	July 21 July 21 July 23	Slight Slight 47 h
87E00219	Normal	N/A	N/A
87E00226	Normal	N/A	N/A
87E00227	Stain, Brown, Perianal Death	July 21 July 21	Slight 4.5 h

Frest and Korte--34

APPENDIX E (cont.): INDIVIDUAL ANIMAL HISTORIES

FEMALE: 5.62 mg/kg Physostigmine salicylate (cont.)

Animal Number	Clinical Signs		Observed 987)	Severity
87E00234	Increased Salivation	Sep	8	Slight
87E002 3 7	Increased Salivation Death	Sep Sep		Slight 7.1 h
97E00242	Increased Salivation Death	Sep Sep		Slight 6.4 h
37E00249	Stain, Yellow, Ferianal	Sep	19-21	Slight
87E00255	Death	Sep	8	3.7 h
97E00 256	Diarrhea Death	Sep Sep		Slight 3.6 h
87E00261	Diarrhea Prolapsed Uterus Uterus, Necrosis Uterus, Sutured Drainage, Brown, Vulva Drainage, Yellow, Vulva Material, Brown, Aldomen Material, Brown, Hind Le Rough Coat	sep Sep Sep Sep Sep Sep	10 10 12,13 17 19,20	Moderate Moderate Slight Present Slight Moderate Moderate Moderate Moderate
87E00266	Death	Sep	8	6.2 h

FEMALE: 6.31 mg/kg Physostigmine salicylate

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00188 Death	Stain, Brown, Perianal	July 21 July 21	Slight 4.0 h
	Stain, Brown, Perianal eased Salivation h	July 21 July 21 July 22	Slight Present 18 h
87E00195	Normal	N/A	N/A
87E00202	Death	July 21	0.1 h
87E00203	Death	July 22	24 h
87E00222 Diar	Stain, Brown, Perianal rhea	July 21-Aug 3 July 29	
87E00224	Stain, Brown, Perianal	July 21	Slight.
Inact Emac :	iated h Coat	July 21 July 23,24 July 24 July 24 July 25	Present

Frost and Korte--36

FEMALE: 6.65 mg/kg Physostigmine salicylate

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00180	Tremors Increased Salivation Death	July 23 July 23 July 23	Slight Present 5.4 h
87E00183	Death	July 23	3.8 h
87E00184	Not Dosed	N/A	N/A
87E00185	Increased Salivation Death	July 23 July 23	Present 5.4 h
87E00189	Death	July 23	0.03 h
87E00191	Deat h	July 23	0.02 h
87E00197	Death	July 23	6.3 h
87E00213	Normal	N/A	N/A
87E00221	Death	July 23	2.9 h

FEMALE: 6.65 mg/kg Physostigmine salicylate (cont.)

Animal Number	Clinical Signs		Observed .987)	Severity
87E00231	Increased Salivation	Sep	8	Slight
87E00233	Death	Sep	8	2.6 h
87E00241	Hunched Posture Stain, Yellow, Abdomen	Sep Sep	8 9-21	Present Moderate
87E00251	Increased Salivation Rough Coat	Sep Sep		Slight Slight
87E00262	Normal	N/A		N/A
87E00265	Ataxia Increased Salivation Death	Sep Sep Sep	8	Marked Moderate 2.4 h
87E00267	Increased Salivation	Sep	8	Slight
87E00269	Increased Salivation Rough Coat	Sep Sep		Slight Slight

Frost and Korte--38

APPENDIX E (cont.): INDIVIDUAL ANIMAL HISTORIES

FEMALE: 7.08 mg/kg Physostigmine salicylate

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00173	Increased Salivation	July 23	Present
87E00174	Increased Salivation Death	July 23 July 23	Present 5.0 h
87E00175	Death	July 23	6.4 h
87E00178	Increased Salivation Death	July 23 July 23	Present 4.9 h
87E00194	Death	July 23	4.9 h
87E00206	Normal	N/A	N/A
87E00218	Increased Salivation Death	July 23 July 23	Slight 4.8 h
87E00220	Increased Salivation	July 23	Slight

FEMALE: 7.50 mg/kg Physostigmine salicylate

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00198	Normal	N/A	N/A
87E00199	Tremors Death	July 23 July 23	Slight 4.6 h
87E00204	Stain, Yellow, Perianal Increased Salivation Stain, Brown, Perianal	July 23, Aug 5 July 23 Aug 1,2	Slight Present Moderate
87E00205	Stain, Yellow, Perianal Death	July 23 July 23	Slight 4.6 h
87E00207	Death	July 24	24 h
87E00212	Stain, Brown, Perianal	July 23	Slight
87E00216	Normal	N/A	N/A
87E00221	To Group 3	N/A	N/A

Frost and Korte--40

APPENDIX E (cont.): INDIVIDUAL ANIMAL HISTORIES

FEMALE: 7.50 mg/kg Physostigmine salicylate (cont.)

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00229	Inactive	Sep 8	Moderate
	Ataxia	Sep 8	Moderate
	Death	Sep 8	2.4 h
87 E00239	Paralysis, Hind Limb	Sep 9	Marked
	Moribund	Sep 9	Present
	Death	Sep 10	48 h
87E00244	Increased Salivation	Sep 8	Moderate
87EC0247	Increased Salivation	Sep 8	Slight
	Ataxia	Sep 8	Slight
	Death	Sep 8	2.5 h
87E00250	Increased Salivation	Sep 8	Moderate
	Lacrimation	Sep 8	Slight
	Death	Sep 8	4.6 h
87E00258	Increased Salivation	Sep 8	Moderate
	Ataxia	Sep 8	Slight
	Death	Sep 8	2.4 h
87E00259	Increased Salivation	Sep 8	Slight
	Ataxia	Sep 8	Moderate
	Tremors	Sep 8	Slight
	Death	Sep 8	2.3 h
87E002 63	Increased Salivation	Sep 8	Slight
	Stain, Yellow, Abdomen	Sep 16-21	Slight

FEMALE: Vehicle Controls

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00176	Stain, Brown, Perianal Diarrhea	July 23 July 29, Aug 1-3	Slight Present
87E00182	Normal	N/A	N/A
87E00200	Stain, Brown, Perianal Diarrhea	July 23 Aug 2,3	Slight Present
87E00215	Normal	N/A	N/A
87E00225	Normal	N/A	N/A

FEMALE: 4.47 mg/kg Physostigmine salicylate

Animal Number	Clinical Signs	Dates Observed (1987)	Severity
87E00230	Increased Salivation	Sep 10	Slight
87E00236	Increased Salivation Death	Sep 10 Sep 10	Moderate 6.3 h
87E00245	Increased Salivation Stain, Brown, Perianal Stain, Brown, Abdomen Stain, Yellow, Abdomen	Sep 10 Sep 12,13 Sep 16,17 Sep 19-21,23	Moderate Moderate Slight Slight
87E00252	Increased Salivation Stain, Brown, Periasal	Sep 10 Sep 16-23	Slight Marked
87E00253	Increased Salivation Pallor Inactive Material, Brown, Fr. Leg Diarrhea	Sep 10 Sep 12-16 Sep 14-16 Sep 20-23 Sep 21-23	Slight Moderate Moderate Moderate Present
87E002 57	Increased Salivation Loss of Equilibrium Inactive Pale Skin Color Death	Sep 10 Sep 11 Sep 11 Sep 11 Sep 12	Slight Moderate Moderate Present 48 h
87E00260	Normal	N/A	N/A
87E00264	Increased Salivation Stain, Brown, Aidomen Stain, Yellow, Abdomen	Sep 10 Sep 12-17 Sep 19-23	Slight Moderate Slight

FEMALE: 8.91 mg/kg Physostigmine salicylate

Animal Number	Clinical Signs	Dates Ob (198	
87E00235	Increased Salivation Death	Sep 15	
87E00238	Death	Sep 15	6.9 h
87E00240	Increased Salivation Death	Sep 15	
87E00243	Increased Salivation Death	Sep 15	
87E00246	Increased Salivation Death	Sep 15	
87E00248	Increased Salivation	Sep 15	
87E00254	Increased Salivation Ataxia Inactive Death	Sep 15 Sep 15 Sep 15 Sep 15	Moderate Moderate
87E00268	Death	Sep 15	3.7 h

Frost and Korte--44

the manufacture of the winds of the control of the

APPENDIX F: Individual Body Weights

MALES 5.62 mg/kg - Group 1

Animal No.	At Receipt	At Dosing	Day 7	Termination Day 14*
87E00116	230 [†]	300	381	384
87E00124	258	335	-	-
87E00128	244	330	37 7	389
87E00133	237	297	375	387
97E00140	222	266	-	-
87E00147	239	308	257	284
87E00151	216	293	-	-
87E00152	2 35	295	358	359
Mean	235.1	303.0	349.6	360.6
Standard Deviation	13.0	21.9	52. 5	44.5
Std. Error of Mean	4.6	7.7	23.5	19.9

^{*} Weights after an overnight fast.

[†] Weights are given in grams.

MALES 6.31 mg/kg - Group 2

Animal No.	At Receipt	At Dosing	Day 7	Termination Day 14 [*]
87E00115	235†	289	-	~
87E00132	223	292	357	371
87E00137	236	310	375	387
87E00146	199	303	375	391
87E00156	235	291	233	206
87E00163	216	279	339	361
87E00167	258	322	295	325
87E00170	239	315	376	388
Mean	230.1	300.1	335.7	347.0
Standard Deviation	17.6	14.8	53.8	66.3
Std. Error of Mean	6.2	5.2	20.3	25.1

^{*} Weights after an overnight fast.

[†] Weights are given in grams.

MALES 6.65 mg/kg - Group 3

Animal No.	At Receipt	At Dosing	Day 7	Termination Day 14*
87E00118	238†	305	341	351
87E00120	252	324	-	-
87E00136	233	306	3 51	362
87E00143	233	351	419	431
87E00144	196	303	-	-
87E00149	195	210	-	-
87E001 68	240	329	391	420
87E00171	238	308	-	-
Mean	228.1	304.5	375.5	391.0
Standard Deviation	21.0	41.6	36.2	40.3
Std. Error of Mean	7.4	14.7	18.1	20.2

^{*} Weights after an overnight fast.

[†] Weights are given in grams.

MALES 7.08 mg/kg - Group 4

Animal No.	At Receipt	At Dosing	Day 7	Termination Day 14*
87E00122	220†	298	-	-
87E00123	252	339	-	
87E00127	230	298	351	368
87E00131	236	321	-	~
87E00138	218	304	367	389
87E00142	202	289	341	351
87E00159	247	310	-	~
87E00165	226	273	338	346
Mean	228.9	304.0	349.3	363.5
Standard Deviation	16.2	20.0	13.0	19.4
Std. Error of Mean	5.7	7.1	6.5	9.7

^{*} Weights after an overnight fast.

[†] Weights are given in grams.

MALES 7.50 mg/kg - Group 5

Animal No.	At Receipt	At Dosing	Day 7	Termination Day 14*
87E00117	236 [†]	302	355	374
87E00119	248	327	398	410
87E00141	252	306	-	-
37E00150	214	330	-	-
87E00153	226	313	-	~
87E00154	218	269	325	315
87E00157	200	265	-	-
87E00166	237	301	-	-
Mean	228.9	301.4	359.3	366.3
Standard Deviation	17.7	24.3	36.7	48.0
Std. Error of Mean	6.3	8.6	21.2	27.7

^{*} Weights after an overnight fast.
† Weights are given in grams.

APPENDIX F (cont.): Individual Body Weights

FEMALES 5.62 mg/kg - Group 1

At At Termination Animal No. Receipt Dosina Day 7 Day 14* 87E00172 244† 279 333 338 87E00177 233 262 317 322 87E00186 216 280 87E00201 209 263 324 303 87E00211 248 386 87E00219 238 299 352 370 87E00226 226 266 314 309 87E00227 229 282 87E00234 211 308 369 372 87E00237 259 312 87E00242 254 276 87E00249 209 278 360 357 87E00255 237 294 87E00256 233 263 87E00261 211 238 229 246 37E00266 273 314 Mean 233.2 287.5 324.8 327.1 Standard Deviation 19.3 33.4 43.7 42.0 Std. Error of Mean 4.8 8.4 15.4 14.9

^{*}Weights after an overnight fast.

[†]Weights are given in grams.

FEMALES 6.31 mg/kg - Group 2

Animal No.	At Receipt	At Dosing	Day 7	Termination Day 14*
87E00188	222†	252	-	_
87E00193	217	263	-	-
87E00195	231	273	323	337
87E00202	265	326	-	-
87E00203	220	255	-	-
87E00222	229	260	314	315
87E00224	239	295	347	351
87E00228	218	263	-	-
Mean	230.1	273.4	328.0	334.3
Standard Deviation	16.0	25.1	17.1	18.1
Std. Error of Mean	5.6	8.9	9.8	10.5

^{*} Weights after an overnight fast.

[†] Weights are given in grams.

APPENDIX F (cont.): Individual Body Weights

FEMALES 6.65 mg/kg - Group 3

Animal No.	At Receipt	At Dosing	Day 7	Termination Day 14*
87E00180	226†	283	-	-
87E00183	233	299	-	-
87E00185	205	272	-	-
87E00189	225	304	-	-
87E00191	235	301	-	-
87E00197	258	309	-	-
87E00213	235	289	331	338
87E00221	191	277	-	-
87E00231	237	294	358	377
87E00233	198	284	-	-
87E00241	296	324	384	385
87E00251	273	300	341	358
87E00262	249	266	336	339
87E00265	222	298	-	-
87E00267	246	284	341	346
87E00269	233	252	295	301
Mean	235.1	289.8	340.9	349.1
Standard Deviation	26.6	17.8	27.0	28.0
Std. Error of Mean	6.6	4.4	10.2	10.6

^{*} Weights after an overnight fast.

[†] Weights are given in grams.

Frost and Korte--52

FEMALES 7.03 mg/kg - Group 4

Animal No.	At Receipt	At Dosing	Day 7	Termination Day 14*
87E00173	237†	289	336	336
87E00174	243	288	-	-
87E00175	232	305	-	-
87E00178	253	299	-	-
87E00194	237	272	-	<u>-</u>
87E00206	235	280	352	351
87E00218	238	291	-	-
87E00220	215	277	334	314
Mean	236.3	287.6	340.7	333.7
Stan dard Deviation	10.7	11.1	9.9	18.6
Std. Error of Mean	3.8	3.9	5.7	10.7

^{*} Weights after an overnight fast.

[†] Weights are given in grams.

APPENDIX F (cont.): Individual Body Weights

FEMALES 7.50 mg/kg - Group 5

Animal No.	At Receipt	At Dosing	Day 7	Termination Day 14*
87E00198	237†	271	345	340
87E00199	241	289	-	-
87E00204	225	244	274	286
87E00205	231	281	-	-
87E00207	241	306	-	-
87E00212	244	238	295	305
87E00216	236	309	383	390
87E00279	225	239	-	-
87E00239	254	313	-	-
87E00244	270	303	356	369
87E00247	277	294	-	-
87E00250	254	267		-
87E00258	217	281	-	-
87E00259	236	268	-	-
87E00263	255	268	324	321
Mean	242.9	278.1	329.5	335.2
Standard Deviation	16.6	24.8	40.3	39.2
Std. Error of Mean	4.3	6.4	16.4	16.0

^{*} Weights after an overnight fast.

[†] Weights are given in grams.

APPENDIX F (cont.): Individual Body Weights

VEHICLE CONTROLS - Group 6

Animal No.	At Receipt	At Dosing	Day 7	Termination Day 14*
		MALE	s	n december the control section for the control of control of the c
87E00121 87E00125 87E00135 87E00155 87E00158	223 [†] 238 233 232 221	291 326 326 299 283	361 386 406 359 346	349 403 431 369 349
Mean	229.4	305.0	371.6	380.2
Standard Deviation	7.2	20.0	24.1	36.0
Std. Error of Mean	3.7	8.9	10.8	16.1
		FEMAL	ES	
87E00176 87E00182 87E00200 87E00215 87E00225	225 188 222 226 223	278 265 299 275 267	328 320 336 324 339	326 322 325 330 343
Mean	216.8	276.8	329.4	329.2
Standard Deviation	16.2	13.5	8.0	8.2
Std. Error of Mean	7.2	ບົ.0	3.6	3.7

^{*} Weights after an overnight fast.

† Weights are given in grams.

FEMALES 4.47 mg/kg - Group 7

Animal No.	At Receipt	At Dosing	Day 7	Termination Day 14*
87E00230	2081	277	322	333
87E00236	277	384	-	-
87E00245	241	294	349	359
87E00252	250	292	356	360
87E00253	226	273	225	207
87E00257	208	290	-	-
87E00260	215	244	302	257
87E00264	255	296	352	364
Mean	235.0	293.8	317.7	313.3
Standard Deviation	25.0	40.3	50.0	65.9
Std. Error of Mean	8.8	14.2	20.4	26.9

^{*} Weights after an overnight fast.

[†] Weights are given in grams.

A STATE OF THE PROPERTY OF THE PARTY OF THE

FEMALES 8.91 mg/kg - Group 8

Animal No.	At Receipt	At Dosing	Day 7	Termination Day 14*
87E00235	283†	378	_	-
87E00238	225	348	-	
87E00240	290	359	_	-
87E00243	252	334	-	-
87200246	232	368	-	-
87E00248	242	299	-	-
87E00254	230	317	-	-
87E00268	268	336	-	-
Mean	252.8	342.4		-
Standard Deviation	25.0	26.4	-	-
Std. Error of Mean	8.8	9.3	-	-

^{*} Weights after an overnight fast.

[†] Weights are given in grams.

APPENDIX G: Pathology Report

Pathology Report GLP 87008

Acute Oral Toxicity

- I. Compound: Physostigmine salicylate Species: <u>Cavia porcellus</u>, Hartley, young adult.
- II. Principal Investigator: CPT Denzil F. Frost Pathologist: MAJ Charles B. Clifford

III. Comment: No gross lesions were observed in animals surviving the fourteen days of the study. Gross observations in cases of unscheduled deaths are compatible with either generalized increased parasympathetic tone (perioral staining and intussusception) or common incidental findings (hepatic necrosis) of little clinical significance in guinea pigs. No evidence of direct tissue damage due to physostigmine salicylate was observed in any animal.

Charles B. CLIFFORD, DVM

MAJ, VC

Division of Pathology

12 November 1987/dbj

APPENDIX G (cont.): Pathology Report

ATTACHMENT:

GROUP #1 (5.62 mg/kg) 16 animals, dosed 21 Jul 87, 10 animals sacrificed 4 Aug 87.

			NECROPS	ΣΥ			
ANIMAL ID#	LAIR ACC#	SEX	DATE	_	DIAGNOSES		
87EØØ116	41444	M	4 Aug	-	No lesions recogrized		
128	41445	М	4 Aug	-	No lesions recognized		
133	41447	M	4 Aug		No lesions recognized		
147	41450	М	4 Aug		No lesions recognized		
152	41451	М	4 Aug		No lesions recognized		
172	41456	F	4 Aug		No lesions recognized		
177	41457	F	4 Aug	97	No lesions recognized		
201	41459	F	4 Aug	87	No lesions recognized		
219	41460	F	4 Aug	87	No lesions recognized		
226	41463	F	4 Aug	87	No lesions recognized		
GROUP #1 Spontaneous deaths, 6 animals							
87EØØ124	41344	М	21 Jul	87	Serous oral discharge		
140	41343	M	21 Jul	87	Serous oral discharge		
151	41348	М	22 Jul	87	Brown perioral staining		
186	41341	F	21 Jul		No lesions recognized		
211	42065	F	23 Jul		No lesions recognized		
227	41342	F	21 Jul	-	Serous oral discharge		
GROUP #2 sacrificed	(6.31 mg/kg), 10 1 4 Aug 87.	6 anima	ls, dosed	21	Jul 87, 10 animals		
87EØØ132	41446	М	4 Aug	87	No lesions recognized		
137	41448	М	4 Aug	87	No lesions recognized		
146	41449	M	4 Aug	87	No lesions recognized		
156	41452	M	4 Aug	87	No lesions recognized		
163	41453	М	4 Aug		No lesions recognized		
167	41454	M	4 Aug		No lesions recognized		
173	41455	М	4 Aug		No lesions recognized		
195	41458	F	4 Aug		No lesions recognized		
222	41461	F	4 Aug		No lesions recognized		
224	41462	F	4 Aug		No lesions recognized		
GROUP #2	Spontaneous dear	ths, 6	animals				
87600115	4 - 49	м	23 Jul	87	No lesions recognized		
198	41:47	F	22 Jul	87	No lesions recognized		
193	41345	F	22 Jul	87	Serous oral discharge,		
					mild, focal, hepatic		
200	41 240	F.	21 Jul	07	necrosis.		
2 02	41340	ť	21 301	87	Ingesta present around and in mouth, mild hemopericardium, mild, focal, hepatic necrosis.		
203	41346	F	22 Jul	87	No lesions recognized		
229	41378	F	25 Jul	87	No lesions recognized		

APPENDIX G (cont.): Pathology Report
ROUP #3 (6.65 mg/kg), 24 animals, dosed 23 Jul 87, 5 anima

The same of the sa

GROUP #3 (6.65 mg/kg), 24 animals, dosed 23 Jul 87, 5 animals sacrificed 6 Aug 87.

			NECROPSY	
ANIMAL ID	LAIR ACC	C# SEX	DATE	DIAGNOSES
87EØØ118	41482	M	6 Aug 87	No lesions recognized
136	41488	M	6 Aug 87	No lesions recognized
143	41491	M	6 Aug 87	No lesions recognized
168	41496	М	6 Aug 87	
213	41505	F	6 Aug 87	No lesions recognized
GROUP #3	Spontaneous	deaths, 13	animals, #1	
87EØØ12Ø	41371	М	23 Jul 87	-
144	41375	М	24 Jul 87	
149	41356	M	23 Jul 87	Yellow-brown perioral and
				perianal staining
171	41368	M	23 Jul 87	No lesions recognized
180	41360	F	23 Jul 87	Serous oral discharge
183	41354	F	23 Jul 87	Serous oral discharge
185	41361	F	23 Jul 87	Serous oral discharge
189	42064	F	23 Jul 87	No lesions recognized
191	42063	F	23 Jul 87	Brown perinasal staining
197	41369	F	23 Jul 87	Ingesta around oral
				cavity
221	41357	F	23 Jul 87	Ingesta around oral
		,		cavity
				-

^{*1} Additionally, 87F00184 (Accession #41464), a female was not dosed due to excessive weight loss, and was found dead 30 Jul 87. Gross observations included extensive matting of fur with diarrhea, severe dehydration and emaciation.

GROUP #4 (7.08 mg/kg), 9 animals dosed 23 Jul 87. Seven animals sacrificed 6 Aug 87.

87EØØ127	41486	М	6	Aug	87	No	lesions	recognized
138	41489	M	6	Aug	87	No	lesions	recognized
142	41490	М	6	Aug	87	No	lesions	recognized
165	41495	M	6	Aug	87	No	lesions	recognized
173	41497	F	6	Aug	87	No	lesions	recognized
206	41503	F	6	Aug	87	No	lesions	recognized
220	41508	F	6	Aug	87	No	lesions	recognized

APPENDIX G (cont.): Pathology Report

GROUP #4 Spontaneous deaths, 9 animals

			NECR	OPSY	
ANIMAL II	D# LAIR ACC#	SEX	DA	TE	DIAGNOSES
87EØØ122	41358	М	23 ј	ul 87	Serous oral discharge
123	41355	M	23 J	ul 87	Serous oral discharge
131	41372	M	23 J	ul 87	Serous oral discharge
159	41376	М	24 J	ul 87	Serous oral and ocular
174	41.262	_	0.3		discharge
174 175	41362 41374	F F		ul 37	Brown perioral staining
1/5	41374	r	23 0	ul 87	Green-brown perioral and perianal staining
178	41364	F	23 J	ul 37	Serous oral discharge
194	41367	F	23 J	ul 87	Serous oral discharge
218	41363	F		ul 87	Serous oral discharge
GROUP #5 sacrifice	(7.5 mg/kg) 15 ed 6 Aug 87.	animal	s, dos	eđ 23	Jul 87. 7 animals
87EØØ117	41481	М	6 A	ug 87	No lesions recognized
119	41483	М		ug 87	No lesions recognized
154	41492	M		ug 87	No lesions recognized
198	41500	F		ug 87	No lesions recognized
204	41502	F		ug 87	No lesions recognized
212	41504	F		ug 87	No lesions recognized
216	41507	F		ug 87	No lesions recognized
GROUP #5	Spontaneous dea	ths, 8 a	nnimal:	s	
87EØØ141	41373	М	23 .7	JL 87	Serous oral discharge
150	41366	M	23 J	al 87	No lesions recognized
153	41379	M	25 J	ul 87	Multifocal, mild hepatic
	41.200		25 -		necrosis
157	41380	M	-	ul 87	No lesions recognized
166	41370	M		ul 87	Serous oral discharge
199	41365	F		ul 87	Serous oral discharge
205	41359	F		ul 87	Serous oral discharge
237	41377	F	24 J	ul 87	No lesions recognized
GROUP #6	(Control Group ที	mg/kg)	lØ an	imals	, all sacrificed 6 Aug 87
87EØØ121	41194	М	6 A	ug 87	No lesions recognized
125	4 / 195	M	6 A	ug 87	No lesions recognized
135	4, 117	M	6 A	ug 87	No lesions recognized
155	41493	М		ug 87	No lesions recognized
158	41494	M		ug 87	No lesions recognized
176	41498	F		ug 87	No lesions recognized
182	41499	i.'		ug 87	No lesions recognized
200	41501	F		ug 87	No lesions recognized
215	41506	F		ug 87	No lesions recognized
225	41509	F	6 A	ug 87	No lesions recognized

APPENDIX G (cont.): Pathology Report

Additional Animals:

GROUP #1 (5.62 mg/kg), 8 animals, dosed 8 Sep 87. Three animals sacrificed 22 Sep 87.

ANIMAL ID#	LAIR ID#	SEX	DIAGNOSES
87EØØ234	41748	F	No lesions recognized
249	41749	F	No lesions recognized
261	41750	F	Weight loss, diarrhea
24-		-	
Spontaneous D	eaths, 5 ani	mals	
237	41711	F	No lesions recognized. Necropsied 9 Sept 1987.
242	41710	F	No lesions recognized. Necropsied 9 Sept 1987.
255	41707	F	No lesions recognized. Necropsied 8 Sept 1987.
256	41708	F	No lesions recognized. Necropsied 8 Sept 1987.
266	41712	F	No lesions recognized. Necropsied 9
			Sept 1987.
GROUP #3 (6.6 sacrificed 22		animals	, dosed 8 Sep 87. Six animals
87EØØ231	41742	F	No lesions recognized
241	41743	F	No lesions recognized
251	41744	F	No lesions recognized
262	41745	F	No lesions recognized
267	41746	F	No lesions recognized
269	41747	F'	No lesions recognized
Spontaneous I	eaths, 2 ani	mals. N	ecropsied: 8 Sep 87
233	41701	F	No lesions recognized
265	41702	F	No lesions recognized
			<u></u>
GROUP #5 (7.5 sacrificed 22		nimals,	dosed 8 Sep 87. Three animals
87EØØ244	41740	F	No lesions recognized
250	41709	F	No lesions recognized
263	41741	F	No lesions recognized
Spontaneous I stated.)		_	(Necropsied 8 Sept 87 unless otherwise
229	41705	F	No lesions recognized.
239	41713	F	<pre>10 cm intussusception at ileocolic junction, with necrosis and hemorrhage. Necropsied 10 Sep 87.</pre>
247	41704	F	No lesions recognized.
258	41703	F	No lesions recognized.
259	41706	F	No lesions recognized.

APPENDIX G (cont.): Pathology Report

GROUP #7 (4.47 mg/kg), 8 animals, dosed 10 Sep 87. Six animals sacrificed 24 Sep 87.

ANIMAL ID#	LAIR ID#	SEX	DIAGNOSES
87EØØ23Ø	41755	F	No lesions recognized
245	41756	F	No lesions recognized
2 52	41757	F	No lesions recognized
253	41758	F	Diarrhea, diminished body fat.
260	41759	£	No lesions recognized
264	41760	F	No lesions recognized
Spontaneous D	Deaths, 2 ani	mals	
236	41719	F	No lesions recognized. Necropsied 11 Sept 1987.
257	41720	F	Ileocolic intussusception with necrosis of the intussusceptum. Necropsied 14 Sept 1987.
GROUP #8 (8.9 deaths.)1 mg/kg), 8	animals,	dosed 15 Sep 87. All spontaneous
87EØØ235	41724	F	No lesions recognized
238	41726	F	No lesions recognized
240	41728	F	No lesions recognized. Necropsied 16 Sept 1987
243	41723	F	No lesions recognized
246	41725	F	No lesions recognized
248	41727	F	Ileum congestion with marked congestion of Peyer's Patches. Neuropsied 16 Sept 1987.
254	41721	F	No lesions recognized.
268	41722	F	No lesions recognized.

OFFICIAL DISTRIBUTION LIST

Commander
US Army Medical Research
& Development Command
ATTN: SGRD-RMS/Mrs. Madigan
Fort Detrick, MD 21701-5012

Defense Technical Information Center ATTN: DTIC/DDAB (2 copies) Cameron Station Alexandria, VA 22304-6145

Office of Under Secretary of Defense Research and Engineering ATTN: R&AT (E&LS), Room 3D129 The Pentagon Washington, DC 20301-3080

DASG-AAFJML Army/Air Force Joint Medical Library Offices of the Surgeons General 5109 Leesburg Pike, Room 670 Falls Church, VA 22041-3258

HQ DA (DASG-ZXA) WASH DC 20310-2300

Commandant
Academy of Health Sciences
US Army
ATTN: HSHA-CDM
Fort Sam Houston, TX 78234-6100

Uniformed Services University of Health Sciences Office of Grants Management 4301 Jones Bridge Road Bethesda, MD 20814-4799

US Army Research Office ATTN: Chemical and Biological Sciences Division PO Box 12211 Research Triangle Park, NC 27709-2211

Director ATTN: SGRD-UWZ-L Walter Reed Army Institute of Research Washington, DC. 20307-5100

Commander
US Army Medical Research Institute
of Infectious Diseases
ATTN: SGRD-ULZ-A
Fort Detrick, MD 21701-5011

Commander
US Army Medical Bioengineering Research
and Development Laboratory
ATTN: SGRD-UBG-M
Fort Detrick, Bldg 568
Frederick, MD 21701-5010

Commander
US Army Medical Bioengineering
Research & Development Laboratory
ATTN: Library
Fort Detrick, Bldg 568
Frederick, MD 21701-5010

Commander
US Army Research Institute
of Environmental Medicine
ATTN: SGRD-UE-RSA
Kansas Street
Natick, MA 01760-5007

Commander
US Army Research Institute of
Surgical Research
Fort Sam Houston, TX 78234-6200

Commander
US Army Research Institute of
Chemical Defense
ATTN: SGRD-UV-AJ
Aberdeen Proving Ground, MD 21010-5425

Commander
US Army Aeromedical Research
Laboratory
Fort Rucker, Al. 36362-5000

AIR FORCE Office of Scientific Research (NL) Building 410, Room A217 Bolling Air Force Base, DC 20332-6448

USAF School of Aerospace Medicine Document Section USAFSAM/TSKD Brooks Air Force Base, TX 78235-5301

Head, Biological Sciences Division OFFICE OF NAVAL RESEARCH 800 North Quincy Street Arlington, VA 22217-5000